Cervical cancer could become a disease of the past in wealthy nations within the next two decades, but a stark global inequality threatens to leave poorer countries behind. A new study from Canadian researchers shows that while high-income countries are on track to eliminate cervical cancer through human papillomavirus (HPV) vaccination and screening programs, low-income countries face a widening crisis without significant international investment and support.

Why Are Some Countries Succeeding While Others Fall Behind?

Canada is forecast to eliminate cervical cancer by 2048, joining countries like Australia and several European nations in achieving this milestone. The research, published in The Lancet by a team from Université Laval and the CHU de Québec, reveals the stark disparity in outcomes. Currently, cervical cancer incidence in lower-income countries is three times higher than in wealthier countries. Without intervention, that gap could explode to 12 times higher by the end of the century, or even 40 times higher when compared directly to Canada.

The difference comes down to access and resources. High-income countries have successfully implemented robust HPV vaccination programs and cervical screening initiatives, while many lower-income nations struggle with limited vaccination coverage and minimal screening capacity. This isn't a matter of willpower; it's a matter of infrastructure and funding.

What's the WHO's Roadmap for Eliminating Cervical Cancer?

In 2020, the World Health Organization (WHO) established three specific targets for eliminating cervical cancer, defined as reducing the incidence rate to fewer than 4 cases per 100,000 women. These targets include vaccinating 90% of girls before age 15, screening 70% of women, and treating 90% of precancerous lesions and cancers.

The Canadian research team assessed whether countries were on track to meet these goals. The findings were encouraging for wealthy nations but sobering for developing regions. High-income countries are hitting the targets, with some even expanding programs to vaccinate boys, which provides indirect protection to girls. However, many countries with the highest cervical cancer burden have low vaccination coverage and limited screening capacity, putting them far off track.

How Can Lower-Income Countries Catch Up?

The good news is that solutions exist, though they require substantial investment and strategic planning. Researchers have identified several practical approaches that could help lower-income countries achieve cervical cancer elimination without waiting decades:

• Lower-Cost Vaccines: New, more affordable HPV vaccines are becoming available on the market, making vaccination programs financially feasible for resource-limited settings.
• Simplified Dosing Schedules: Administering just one dose of the HPV vaccine instead of two reduces costs and logistical complexity while maintaining effectiveness.
• Catch-Up Campaigns: Vaccinating adolescents and young adults who missed the vaccine during pre-adolescence can rapidly increase population immunity.
• Boys' Vaccination Programs: Vaccinating boys provides indirect protection to girls and reduces overall transmission, even without universal female coverage.

"The good news is that there are ways to catch up, but they will require significant investment from countries and international organisations," explained Dr. Mélanie Drolet, an epidemiologist at the CHU de Québec-Université Laval Research Center.

Dr. Mélanie Drolet, Epidemiologist at CHU de Québec-Université Laval Research Center

The research team modeled various prevention scenarios to understand the potential impact. The most promising approach combines achieving WHO targets with universal vaccination for both girls and boys, plus catch-up campaigns for those who missed earlier vaccination. This comprehensive strategy could prevent nearly 37 million cancer cases by the end of the century.

For countries where large-scale screening programs are difficult to implement, universal vaccination with catch-up campaigns offers a realistic alternative. This approach could enable cervical cancer elimination in most countries without requiring expensive screening infrastructure, achieving results equivalent to the full WHO targets.

What Role Does Screening Play in Cancer Prevention?

While vaccination is the cornerstone of cervical cancer prevention, screening remains crucial for detecting precancerous changes and early-stage disease. At the 6th Siloam Oncology Summit in Jakarta, medical professionals emphasized the distinction between screening and early detection, two related but different approaches to catching cancer before it becomes life-threatening.

"Screening is designed for healthy, asymptomatic populations and involves large numbers of individuals. In contrast, early detection is a clinical service directed at a smaller population, or even single individuals, who are already exhibiting symptoms," explained Dr. Santi Christiani Gultom, a hematologist and medical oncologist at MRCCC Siloam Semanggi.

Dr. Santi Christiani Gultom, Hematologist and Medical Oncologist at MRCCC Siloam Semanggi

Screening programs must meet specific criteria to be worthwhile. They require a significant public health burden in the region, must be practical and cost-effective, and need to reduce overall cancer incidence. The screening tests themselves should be simple, safe, and widely acceptable to the public. Most importantly, effective treatment must be readily available when a positive result is found.

The path forward is clear: wealthy nations are winning the fight against cervical cancer through vaccination and screening, but global health equity demands that lower-income countries receive the resources and support needed to follow the same path. Without urgent action, cervical cancer will remain a devastating disease in the world's poorest regions while it becomes nearly extinct in the richest ones.